Dae Gon Ha
Stock Analyst at Stifel
(2.74)
# 1,840
Out of 4,765 analysts
48
Total ratings
33.33%
Success rate
0.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dae Gon Ha
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EDIT Editas Medicine | Downgrades: Hold | $11 → $3 | $1.37 | +118.98% | 4 | Dec 13, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $59 → $74 | $49.03 | +50.93% | 2 | Oct 1, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Hold | $22 → $3 | $2.90 | +3.45% | 4 | Sep 12, 2024 | |
| INZY Inozyme Pharma | Initiates: Buy | $16 | $1.00 | +1,500.48% | 1 | Sep 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $80 → $64 | $9.22 | +594.14% | 2 | Sep 11, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $204 → $220 | $177.37 | +24.03% | 4 | Sep 11, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $48 → $66 | $44.56 | +48.11% | 3 | Jun 20, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $124 → $127 | $39.25 | +223.57% | 2 | May 31, 2024 | |
| ABEO Abeona Therapeutics | Initiates: Buy | $21 | $5.28 | +297.73% | 1 | May 30, 2024 | |
| VERV Verve Therapeutics | Maintains: Buy | $56 → $40 | $6.15 | +550.41% | 3 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $8.50 | +464.71% | 4 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $1.72 | +946.51% | 1 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7 | $0.78 | +797.44% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $50.24 | -50.24% | 4 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $16 | $8.81 | +81.61% | 3 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $285 | $11.89 | +2,296.13% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $1.74 | +1,049.43% | 1 | May 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.42 | - | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $24.37 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $7.54 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.15 | +943.48% | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $490 | $5.21 | +9,304.99% | 2 | Oct 23, 2017 |
Editas Medicine
Dec 13, 2024
Downgrades: Hold
Price Target: $11 → $3
Current: $1.37
Upside: +118.98%
Soleno Therapeutics
Oct 1, 2024
Maintains: Buy
Price Target: $59 → $74
Current: $49.03
Upside: +50.93%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Hold
Price Target: $22 → $3
Current: $2.90
Upside: +3.45%
Inozyme Pharma
Sep 12, 2024
Initiates: Buy
Price Target: $16
Current: $1.00
Upside: +1,500.48%
Intellia Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $80 → $64
Current: $9.22
Upside: +594.14%
Krystal Biotech
Sep 11, 2024
Maintains: Buy
Price Target: $204 → $220
Current: $177.37
Upside: +24.03%
Mirum Pharmaceuticals
Jun 20, 2024
Maintains: Buy
Price Target: $48 → $66
Current: $44.56
Upside: +48.11%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Buy
Price Target: $124 → $127
Current: $39.25
Upside: +223.57%
Abeona Therapeutics
May 30, 2024
Initiates: Buy
Price Target: $21
Current: $5.28
Upside: +297.73%
Verve Therapeutics
Apr 3, 2024
Maintains: Buy
Price Target: $56 → $40
Current: $6.15
Upside: +550.41%
Sep 13, 2023
Reiterates: Buy
Price Target: $48
Current: $8.50
Upside: +464.71%
Apr 18, 2023
Initiates: Buy
Price Target: $18
Current: $1.72
Upside: +946.51%
Mar 24, 2023
Maintains: Buy
Price Target: $12 → $7
Current: $0.78
Upside: +797.44%
Jun 17, 2022
Maintains: Buy
Price Target: $23 → $25
Current: $50.24
Upside: -50.24%
Nov 15, 2021
Upgrades: Buy
Price Target: $12 → $16
Current: $8.81
Upside: +81.61%
Sep 7, 2021
Initiates: Buy
Price Target: $285
Current: $11.89
Upside: +2,296.13%
May 3, 2021
Initiates: Buy
Price Target: $20
Current: $1.74
Upside: +1,049.43%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $6.42
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $24.37
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $7.54
Upside: -
Jun 17, 2020
Initiates: Buy
Price Target: $12
Current: $1.15
Upside: +943.48%
Oct 23, 2017
Maintains: Outperform
Price Target: $600 → $490
Current: $5.21
Upside: +9,304.99%